Acadian Asset Management
CNSP icon

Acadian Asset Management’s CNS Pharmaceuticals CNSP Stock Holding History

Acadian Asset Management’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$49K – 1667
2023
Q2 		$49K Buy
+1
New +$53.7K ﹤0.01% 1536

Other funds holding CNSP

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
FWA
FSM Wealth Advisors Cleveland, Ohio $939M AUM 22.84% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GRP
Global Retirement Partners San Rafael, California $5.64B AUM

Acadian Asset Management's CNSP Position: Q3 2023 in Review

Acadian Asset Management sold out of CNS Pharmaceuticals (CNSP) in Q3 2023, closing a stake of 1 share — an estimated $49K sold.

Acadian Asset Management first reported a position in CNSP in Q2 2023 and held it in 1 quarter. The position peaked at $49K in Q2 2023. 5 funds tracked by Wall St. Rank hold CNSP as of Q3 2023.

  • Acadian Asset Management reported no remaining CNS Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Acadian Asset Management sold 1 CNS Pharmaceuticals share in Q3 2023, an estimated $49K.
  • Acadian Asset Management first reported a position in CNS Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Acadian Asset Management's CNS Pharmaceuticals position peaked at $49K in Q2 2023.
  • 5 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q3 2023.

Based on Acadian Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.